(Q37047969)

English

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma

scientific article published on May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase II clinical trial

0 references

0 references

author name string

Jeffrey A Sosman

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Carole Carrillo

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Walter J Urba

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Lawrence Flaherty

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Michael B Atkins

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Joseph I Clark

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Janet Dutcher

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kim A Margolin

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

James Mier

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jarod Gollob

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

John M Kirkwood

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David J Panka

12

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Nancy A Crosby

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kevin O'Boyle

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Bonnie LaFleur

15

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Marc S Ernstoff

16

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

1 May 2008

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2292-2298

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Regulatory T cells, tumour immunity and immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Role of immature myeloid cells in mechanisms of immune evasion in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

CD4+ Tregs and immune control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Management of cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Progress in human tumour immunology and immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Alteration of signal transduction in T cells from cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

29 September 2017

All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

27 June 2018

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

27 June 2018

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

4 September 2018

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724516

4 September 2018

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18467720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.13.3165

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

release_j24nhj2oeresznjnej6xkgvrdq

1 reference

https://api.fatcat.wiki/v0/release/j24nhj2oeresznjnej6xkgvrdq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37047969&oldid=2092374412"